A Phase 3 interventional study of Fluticasone Furoate 100mcg/Vilanterol 25mcg and Fluticaosne Propionate 500mcg/Salmeterol 50mcg in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 66 sites in 9 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2018-08-31.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, none of them phase 3. fluticasone furoate · Pulmonary Disease, Chronic Obstructive.
Among the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, this one is the 8th largest by enrollment, is one of 4 that started in 2011, is one of 7 in phase 3, and was the 4th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive are open now, in 2 countries. Recruiting first, the newest first:
Western University, Canada · Sites in Canada
Ages 50–85
National Institute of Respiratory Diseases, Mexico · Sites in Mexico
Ages 35–85 · Women only
By country, each count listing its studies:
fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 528 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 229 across the 25 interventional studies. Of the 21 that completed or were terminated, 15 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 25 have an industry lead sponsor. The 5 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline: 7 open now, 8 under way, 5 of them phase 3. Of 264 finished, 141 (53%) have results posted.
Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 60th largest by enrollment of the 236 interventional ones that give a count, is one of 26 that started in 2011, is one of 65 in phase 3, and was the 117th registered.
GlaxoSmithKline’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2000.
1 of the studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07192016Western University, Canada129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 276 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of Fluticasone Furoate/Vilanterol 100/25mcg once daily compared with Salmeterol/Fluticasone Propionate 50/500mcg twice daily over a 12-week treatmen period in subjects with COPD.
This is a randomized, double-blind, double-dummy, multi-centre parallel group study. Subjects who meet the eligilibilty criteria at Screening and meet the randomization criteria at the end of a 2-week Run-In period will enter a 12-week Treatment period. There will be a 7-day Follow-up period after the treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inhaled Corticosteroid (ICS)/Long Acting Beta Agonist (LABA)
Drug: Fluticasone Furoate 100mcg/Vilanterol 25mcg
Inhaled Corticosteroid (ICS)/Long Acting Beta Agonist (LABA
Drug: Fluticaosne Propionate 500mcg/Salmeterol 50mcg
Drug page: Fluticasone furoate
Inhalation Powder
Inhalation Powder
Change From Baseline Trough in 24-hour Weighted-mean FEV1 on Treatment Day 84
Pulmonary function was measured by forced expiratory volume in one second (FEV1). The weighted mean was calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, 30, and 60 minutes (min) and 2, 4, 6, 8, 12, 13, 14, 16, 20, and 24 hours on Treatment Day 84. Baseline trough FEV1 was the mean of the two assessments made 30 and 5 minutes pre-dose on Treatment Day 1. Change from Baseline was calculated as the average of the Day 84 values minus the Baseline value.
Time frame: Baseline and Day 84
Time to Onset on Treatment Day 1
Time to onset on Treatment Day 1 is defined as the time to an increase of 100 milliliters (mL) from Baseline in FEV1. Time of onset was calculated over 0 to 4 hours (5 min, 15 min, 30 min, 60 min, 120 min, and 240 min) post-dose.
Time frame: Day 1
Change From Baseline in Trough FEV1 on Treatment Day 85
Pulmonary function was measured by forced expiratory volume in one second (FEV1). Trough FEV1 was defined as the 24-hour FEV1 assessment, which was obtained on Day 85. Baseline is defined as the mean of the two assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1.Change from Baseline was calculated as the average of the Day 85 values minus the Baseline value.
Time frame: Baseline and Day 85
| Milestone | Placebo + Salbutamol | Salmeterol/FP 50/500 µg BID | FF/VI 100/25 µg QD |
|---|---|---|---|
| Started | 702 | 0 | 0 |
| Completed | 528 | 0 | 0 |
| Not completed | 174 | 0 | 0 |
| Withdrew: Inclusion/exclusion criteria not met | 66 | 0 | 0 |
| Withdrew: Physician decision | 6 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 |
| Withdrew: Protocol violation | 5 | 0 | 0 |
| Withdrew: Continuation criteria not met | 88 | 0 | 0 |
| Milestone | Placebo + Salbutamol | Salmeterol/FP 50/500 µg BID | FF/VI 100/25 µg QD |
|---|---|---|---|
| Started | 0 | 262 | 266 |
| Completed | 0 | 246 | 243 |
| Not completed | 0 | 16 | 23 |
| Withdrew: Adverse event | 0 | 3 | 6 |
| Withdrew: Lack of efficacy | 0 | 2 | 3 |
| Withdrew: Protocol violation | 0 | 6 | 9 |
| Withdrew: Lost to follow-up | 0 | 1 | 3 |
| Withdrew: Physician decision | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 2 |
Pulmonary function was measured by forced expiratory volume in one second (FEV1). The weighted mean was calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, 30, and 60 minutes (min) and 2, 4, 6, 8, 12, 13, 14, 16, 20, and 24 hours on Treatment Day 84. Baseline trough FEV1 was the mean of the two assessments made 30 and 5 minutes pre-dose on Treatment Day 1. Change from Baseline was calculated as the average of the Day 84 values minus the Baseline value.
| Liters | Salmeterol/FP 50/500 µg BID | FF/VI 100/25 µg QD |
|---|---|---|
| Change From Baseline Trough in 24-hour Weighted-mean FEV1 on Treatment Day 84 | 0.108 ± 0.0145 | 0.130 ± 0.0148 |
Time to onset on Treatment Day 1 is defined as the time to an increase of 100 milliliters (mL) from Baseline in FEV1. Time of onset was calculated over 0 to 4 hours (5 min, 15 min, 30 min, 60 min, 120 min, and 240 min) post-dose.
| Minutes | Salmeterol/FP 50/500 µg BID | FF/VI 100/25 µg QD |
|---|---|---|
| Time to Onset on Treatment Day 1 | 28 (5 to 240) | 16 (5 to 240) |
Pulmonary function was measured by forced expiratory volume in one second (FEV1). Trough FEV1 was defined as the 24-hour FEV1 assessment, which was obtained on Day 85. Baseline is defined as the mean of the two assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1.Change from Baseline was calculated as the average of the Day 85 values minus the Baseline value.
| Liters | Salmeterol/FP 50/500 µg BID | FF/VI 100/25 µg QD |
|---|---|---|
| Change From Baseline in Trough FEV1 on Treatment Day 85 | 0.088 ± 0.0154 | 0.111 ± 0.0155 |
Collected over Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication until Follow-up (up to 12 weeks).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Salmeterol/FP 50/500 µg BID | — | 3/262 (1.1%) | 30/262 (11.5%) |
| FF/VI 100/25 µg QD | — | 6/266 (2.3%) | 32/266 (12%) |
| Event | Salmeterol/FP 50/500 µg BID | FF/VI 100/25 µg QD |
|---|---|---|
| PneumoniaInfections and infestations | 2/262 | 1/266 |
| Atrial fibrillationCardiac disorders | 0/262 | 2/266 |
| SialoadenitisInfections and infestations | 1/262 | 0/266 |
| Infective exacerbation of chronic obstructive airways diseasInfections and infestations | 0/262 | 1/266 |
| Angina pectorisCardiac disorders | 0/262 | 1/266 |
| Coronary artery diseaseCardiac disorders | 0/262 | 1/266 |
| Food poisoningGastrointestinal disorders | 0/262 | 1/266 |
| Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/262 | 1/266 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/262 | 1/266 |
| Event | Salmeterol/FP 50/500 µg BID | FF/VI 100/25 µg QD |
|---|---|---|
| HeadacheNervous system disorders | 18/262 | 20/266 |
| NasopharyngitisInfections and infestations | 12/262 | 8/266 |
| Back painMusculoskeletal and connective tissue disorders | 3/262 | 10/266 |
| Age, Continuous(Years) | Salmeterol/FP 50/500 µg BID | FF/VI 100/25 µg QD | Total |
|---|---|---|---|
| Mean | 62.9 ± 9.07 | 63.0 ± 8.10 | 62.9 ± 8.59 |
| Sex: Female, Male(Participants) | Salmeterol/FP 50/500 µg BID | FF/VI 100/25 µg QD | Total |
|---|---|---|---|
| Female | 41 | 54 | 95 |
| Male | 221 | 212 | 433 |
| Race/Ethnicity, Customized(participants) | Salmeterol/FP 50/500 µg BID | FF/VI 100/25 µg QD | Total |
|---|---|---|---|
| African American/African Heritage | 1 | 0 | 1 |
| Asian-South East Asian Heritage | 53 | 48 | 101 |
| White-Arabic/North African Hertage | 2 | 1 | 3 |
| White/Caucasian/European Heritage | 206 | 217 | 423 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Feb 2011, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 1 year 9 months after primary completion. A results delay was requested in Apr 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone furoate
Pulmonary Disease, Chronic Obstructive →